At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 372 enrolled
Drug / intervention
B244 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double Blinded, Phase IIb/III, Decentralized Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Participants With Mild to Moderate Acne Vulgaris
In Brief
A Phase 3 clinical trial evaluating B244 and Placebo for Acne Vulgaris. Completed, enrolled 372 participants across 1 site.
Detailed Summary
The purpose of this study is to demonstrate the safety, tolerability and efficacy of B244 administered over 12 weeks to participants with mild to moderate acne vulgaris relative to placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedJul 2016
Enrollment StartAug 2016
Primary CompletionJul 2017
TodayJul 2026
First PostedJul 13, 2016
Enrollment StartAug 1, 2016
Primary CompletionJul 19, 2017
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 10.0 years ago
Interventions
B244biological
4 pumps of spray to saturate the entire face applied BID. Applications should occur in the morning and at night for 12 weeks.
Placebobiological
4 pumps of spray to saturate the entire face applied BID. Applications should occur in the morning and at night for 12 weeks.